MedPath

Secondary Protective effect of ca-antagonist for ischemic heart attack randominzed parallel comparison with beta-blocker trial

Not Applicable
Conditions
Ischemic heart disease (post-myocardila infarction angina, angina pectoris)
Registration Number
JPRN-UMIN000000930
Lead Sponsor
ippon Medical School
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
800
Inclusion Criteria

Not provided

Exclusion Criteria

1) previous history of hypersensitivity or intolerance of atenolol or benidipine 2) cardiogenic shock 3)diabetic ketoacidosis, metabolic acidosis 4)severe or symptomatic bradycardia, atrioventricular block (II, III degree), sinoatrial block, sick sinus syndrome 5)critical arrhythmia 6)right ventricular failure with pulmonary hypertension 7)congestive heart failure 8)hypotension 9)severe peripheral arterial disease (gangrene etc) 10)untreated pheochromocytoma 11)any women who is pregnant or breastfeeding, or expecting to conceive within the projected duration of the study 12)severe hepatic failure (total bilirubin >2.0mg/dL) 13)severe renal failure (serum creatinin >3.0mg/dL) 14)infection, paralytic or obstractive ileus 15)ongoing or planning treatment with anti-cancer drugs 16)other serious illness or significant abnormalities that the investigator judges inappropriate for the study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
cardiovascular evetns including myocardial infarction, angina, silent myocardial ischemia, taget lesion revascularization, cerebral infarction, intracerebral hemorrhage
Secondary Outcome Measures
NameTimeMethod
1. all death 2. hospitalization due to heart failure etc 3. renal failure (hemodialysis)
© Copyright 2025. All Rights Reserved by MedPath